In a keynote session Tuesday at the Fierce Pharma Week 2025 conference in Philadelphia, Sigler spoke about the decision to open up about her MS diagnosis, the positive impacts it’s had on her life and her advice to pharmas seeking
read moreLundbeck is making a big push on the company’s capital reallocation initiative, handing over its operations in 27 markets to partners. More: Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers Source: fierce
read moreRegeneron and Sandoz have reached a settlement that resolves all patent litigation related to the Swiss company’s biosimilar version of eye disease drug Eylea. More: With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026 Source:
read moreThe private equity firm is looking to attract other private equity buyers to take on the CDMO for a valuation of up to $4 billion, the Financial Times reported on Sept. 6. More: Permira looks to launch B sale of
read more
New partnership aims to fast-track mRNA therapies from lab to clinic More: Quotient Sciences and CPI launch RNA drug development venture Source: News
read more
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex More: Bluejay begins phase 3 trial of brelovitug for hepatitis D Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals